Drug Hunter
Home > M3814
DNA-PK-selective kinase inhibitor
oral efficacy in xenograft radiation models
undisclosed screening and optimization
Mol. Cancer Ther., Mar. 27, 2020
Merck KGaA, Darmstadt, DE
M3814 (Merck KGaA oral DNA-PK selective kinase inhibitor)
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
March 2020
Molecules of the Month
02
February
01
January
03
March
04
April
05
May
06
June
07
July
08
August
09
September
10
October
11
November
12
December
MOTY Nominees
Molecule of the Year